CoChat
Sign Up
Cited by 81

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

A Systematic Review of MicroRNA Expression as Biomarker of Late-Onset Alzheimer’s Disease

Herrera-Espejo, Soraya, Santos-Zorrozua, Borja, Álvarez-González, Paula, Lopez-Lopez, Elixabet, Garcia-Orad, África·2019·Molecular Neurobiology
DOI 10.1007/s12035-019-01676-9
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12035-019-01676-9

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 133

  1. Pan Y, Liu R, Terpstra E, Wang Y, Qiao F, Wang J et al (2016) Dysregulation and diagnostic potential of microRNA in Alzheimer’s disease. J Alzheimers Dis 49(1):1–12 · DOI · Paper page
  2. Wattmo C, Wallin AK, Londos E, Minthon L (2011) Predictors of long-term cognitive outcome in Alzheimer’s disease. Alzheimers Res Ther 3(4):23 · DOI
  3. Ossenkoppele R, Mattsson N, Teunissen CE, Barkhof F, Pijnenburg Y, Scheltens P et al (2015) Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer’s disease. Neurobiol Aging 36(8):2340–2347 · DOI
  4. Cui L, Li Y, Ma G, Wang Y, Cai Y, Liu S et al (2014) A functional polymorphism in the promoter region of microRNA-146a is associated with the risk of Alzheimer disease and the rate of cognitive decline in patients. PLoS One 9(2):e89019 · DOI
  5. Mattsson N, Rosén E, Hansson O, Andreasen N, Parnetti L, Jonsson M et al (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 78(7):468–476 · DOI
  6. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116(2):281–297 · DOI
  7. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92–105. https://doi.org/10.1101/gr.082701.108 · DOI · Paper page
  8. Johanson TM, Skinner JP, Kumar A, Zhan Y, Lew AM, Chong MM (2014) The role of microRNAs in lymphopoiesis. Int J Hematol 100(3):246–253. https://doi.org/10.1007/s12185-014-1606-y · DOI
  9. Shah SZA, Zhao D, Hussain T, Sabir N, Yang L (2018) Regulation of microRNAs-mediated autophagic flux: a new regulatory avenue for neurodegenerative diseases with focus on prion diseases. Front Aging Neurosci 10:139 · DOI
  10. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N et al (2008) Serum microRNAs are promising novel biomarkers. PLoS One 3(9):e3148 · DOI
  11. Edsbagge M, Andreasson U, Ambarki K, Wikkelsø C, Eklund A, Blennow K et al (2017) Alzheimer’s disease-associated cerebrospinal fluid (CSF) biomarkers do not correlate with CSF volumes or CSF production rate. J Alzheimers Dis 58(3):821–828. https://doi.org/10.3233/JAD-161257 · DOI · Paper page
  12. PubMed. https://www.ncbi.nlm.nih.gov/pubmed/ Accessed 2018.
  13. Dweep H, Sticht C, Pandey P, Gretz N (2011) miRWalk--database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 44(5):839–847. https://doi.org/10.1016/j.jbi.2011.05.002 · DOI
  14. Kanehisa M, Goto S (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1):27–30 · DOI · Paper page
  15. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L et al (2011) Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 39(Database issue):D691–D697. https://doi.org/10.1093/nar/gkq1018 · DOI · Paper page
  16. Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R (2015) InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics 16:169. https://doi.org/10.1186/s12859-015-0611-3 · DOI
  17. Lam F, Lalansingh CM, Babaran HE, Wang Z, Prokopec SD, Fox NS et al (2016) VennDiagramWeb: a web application for the generation of highly customizable Venn and Euler diagrams. BMC Bioinformatics. 17(1):401. https://doi.org/10.1186/s12859-016-1281-5 · DOI
  18. Akhter R, Shao Y, Shaw M, Formica S, Khrestian M, Leverenz JB et al (2018) Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer’s disease. Neurobiol Aging 63:110–119 · DOI
  19. Annese A, Manzari C, Lionetti C, Picardi E, Horner DS, Chiara M et al (2018) Whole transcriptome profiling of late-onset Alzheimer’s disease patients provides insights into the molecular changes involved in the disease. Sci Rep 8(1):4282–018-22701-2 · DOI
  20. Kumar S, Reddy PH (2018) MicroRNA-455-3p as a potential biomarker for Alzheimer’s disease: an update. Front Aging Neurosci 10:41 · DOI
  21. Zumkehr J, Rodriguez-Ortiz CJ, Medeiros R, Kitazawa M (2018) Inflammatory cytokine, IL-1beta, regulates glial glutamate transporter via microRNA-181a in vitro. J Alzheimers Dis 63(3):965–975 · DOI
  22. Hara N, Kikuchi M, Miyashita A, Hatsuta H, Saito Y, Kasuga K et al (2017) Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease. Acta Neuropathol Commun 5(1):10-017-0414-z · DOI · Paper page
  23. Kumar S, Vijayan M, Reddy PH (2017) MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease. Hum Mol Genet 26(19):3808–3822 · DOI · Paper page
  24. Ma X, Liu L, Meng J (2017) MicroRNA-125b promotes neurons cell apoptosis and tau phosphorylation in Alzheimer’s disease. Neurosci Lett 661:57–62 · DOI
  25. Moncini S, Lunghi M, Valmadre A, Grasso M, Vescovo VD, Riva P et al (2017) The miR-15/107 family of microRNA genes regulates CDK5R1/p35 with implications for Alzheimer’s disease pathogenesis. Mol Neurobiol 54(6):4329–4342 · DOI
  26. Pichler S, Gu W, Hartl D, Gasparoni G, Leidinger P, Keller A et al (2017) The miRNome of Alzheimer’s disease: consistent downregulation of the miR-132/212 cluster. Neurobiol Aging 50(167):e1–e10
  27. Jesko H, Wilkaniec A, Cieslik M, Hilgier W, Gassowska M, Lukiw WJ et al (2016) Altered arginine metabolism in cells transfected with human wild-type beta amyloid precursor protein (beta APP). Curr Alzheimer Res 13(9):1030–1039 · DOI
  28. Zhao Y, Alexandrov PN, Jaber V, Lukiw WJ (2016) Deficiency in the ubiquitin conjugating enzyme UBE2A in Alzheimer’s disease (AD) is linked to deficits in a natural circular miRNA-7 sponge (circRNA; ciRS-7). Genes. 7:12. https://doi.org/10.3390/genes7120116 · DOI
  29. Zhu QB, Unmehopa U, Bossers K, Hu YT, Verwer R, Balesar R et al (2016) MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer’s disease. Brain 139(Pt 3):908–921 · DOI
  30. Lei X, Lei L, Zhang Z, Cheng Y (2015) Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer’s disease. Int J Clin Exp Pathol 8(2):1565–1574
  31. Santa-Maria I, Alaniz ME, Renwick N, Cela C, Fulga TA, Vactor DV et al (2015) Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest 125(2):681–686 · DOI · Paper page
  32. Smith PY, Hernandez-Rapp J, Jolivette F, Lecours C, Bisht K, Goupil C et al (2015) miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum Mol Genet 24(23):6721–6735 · DOI · Paper page
  33. Weinberg RB, Mufson EJ, Counts SE (2015) Evidence for a neuroprotective microRNA pathway in amnestic mild cognitive impairment. Front Neurosci 9:430 · DOI
  34. Banzhaf-Strathmann J, Benito E, May S, Arzberger T, Tahirovic S, Kretzschmar H et al (2014) MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. EMBO J 33(15):1667–1680 · DOI · Paper page
  35. Long JM, Ray B, Lahiri DK (2014) MicroRNA-339-5p down-regulates protein expression of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem 289(8):5184–5198 · DOI · Paper page
  36. Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM (2014) MicroRNAs in Alzheimer’s disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 35(1):152–158 · DOI · Paper page
  37. Absalon S, Kochanek DM, Raghavan V, Krichevsky AM (2013) MiR-26b, upregulated in Alzheimer’s disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci 33(37):14645–14659 · DOI · Paper page
  38. Hebert SS, Wang W-X, Zhu Q, Nelson PT (2013) A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer’s disease, dementia with Lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis 35(2):335–348 · DOI · Paper page
  39. Lau P, Bossers K, Janky RS, Salta E, Frigerio CS, Barbash S et al (2013) Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol Med 5(10):1613–1634 · DOI · Paper page
  40. Wong HK, Veremeyko T, Patel N, Lemere CA, Walsh DM, Esau C et al (2013) De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer’s disease. Hum Mol Genet 22(15):3077–3092. https://doi.org/10.1093/hmg/ddt164 · DOI · Paper page
  41. Yan H, Xu T, Zhao H, Lee KC, Wang HY, Zhang Y (2013) Isoflurane increases neuronal cell death vulnerability by downregulating miR-214. PLoS One 8(2):e55276 · DOI
  42. Zhao Y, Bhattacharjee S, Jones BM, Dua P, Alexandrov PN, Hill JM et al (2013) Regulation of TREM2 expression by an NF-small ka, CyrillicB-sensitive miRNA-34a. Neuroreport. 24(6):318–323 · DOI
  43. Alexandrov PN, Dua P, Hill JM, Bhattacharjee S, Zhao Y, Lukiw WJ (2012) MicroRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol 3(4):365–373
  44. Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H et al (2012) miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol 72(2):269–277 · DOI · Paper page
  45. Lukiw WJ, Alexandrov PN, Zhao Y, Hill JM, Bhattacharjee S (2012) Spreading of Alzheimer’s disease inflammatory signaling through soluble micro-RNA. Neuroreport. 23(10):621–626
  46. Agostini M, Tucci P, Killick R, Candi E, Sayan BS, di Val Cervo PR et al (2011) Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci U S A 108(52):21093–21098 · DOI
  47. Culpan D, Kehoe PG, Love S (2011) Tumour necrosis factor-alpha (TNF-alpha) and miRNA expression in frontal and temporal neocortex in Alzheimer’s disease and the effect of TNF-alpha on miRNA expression in vitro. Int J Mol Epidemiol Genet 2(2):156–162
  48. Geekiyanage H, Chan C (2011) MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer’s disease. J Neurosci 31(41):14820–14830 · DOI · Paper page
  49. Zovoilis A, Agbemenyah HY, Agis-Balboa RC, Stilling RM, Edbauer D, Rao P et al (2011) microRNA-34c is a novel target to treat dementias. EMBO J 30(20):4299–4308 · DOI · Paper page
  50. Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ (2010) Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. J Biol Chem 285(50):38951–38960 · DOI · Paper page
  51. Faghihi MA, Zhang M, Huang J, Modarresi F, der Brug MPV, Nalls MA et al (2010) Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol 11(5) R56–2010-11-5-r56 · DOI · Paper page
  52. Nunez-Iglesias J, Liu CC, Morgan TE, Finch CE, Zhou XJ (2010) Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer’s disease cortex reveals altered miRNA regulation. PLoS One 5(2):e8898 · DOI
  53. Sethi P, Lukiw WJ (2009) Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer’s disease temporal lobe neocortex. Neurosci Lett 459(2):100–104 · DOI · Paper page
  54. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q et al (2008) The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28(5):1213–1223 · DOI · Paper page
  55. Lukiw WJ (2007) Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus. Neuroreport. 18(3):297–300 · DOI · Paper page
  56. Geekiyanage H, Jicha GA, Nelson PT, Chan C (2012) Blood serum miRNA: non-invasive biomarkers for Alzheimer’s disease. Exp Neurol 235(2):491–496 · DOI
  57. Denk J, Oberhauser F, Kornhuber J, Wiltfang J, Fassbender K, Schroeter ML et al (2018) Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS One 13(5):e0197329 · DOI
  58. Derkow K, Rossling R, Schipke C, Kruger C, Bauer J, Fahling M et al (2018) Distinct expression of the neurotoxic microRNA family let-7 in the cerebrospinal fluid of patients with Alzheimer’s disease. PLoS One 13(7):e0200602 · DOI
  59. Dias IHK, Brown CL, Shabir K, Polidori MC, Griffiths HR (2018) miRNA 933 expression by endothelial cells is increased by 27-hydroxycholesterol and is more prevalent in plasma from dementia patients. J Alzheimers Dis 64(3):1009–1017 · DOI
  60. Manzine PR, Pelucchi S, Horst MA, Vale FAC, Pavarini SCI, Audano M et al (2018) MicroRNA 221 targets ADAM10 mRNA and is downregulated in Alzheimer’s disease. J Alzheimers Dis 61(1):113–123 · DOI
  61. McKeever PM, Schneider R, Taghdiri F, Weichert A, Multani N, Brown RA et al (2018) MicroRNA expression levels are altered in the cerebrospinal fluid of patients with young-onset Alzheimer’s disease. Mol Neurobiol · DOI · Paper page
  62. Piscopo P, Grasso M, Puopolo M, D'Acunto E, Talarico G, Crestini A et al (2018) Circulating miR-127-3p as a potential biomarker for differential diagnosis in frontotemporal dementia. J Alzheimers Dis · DOI · Paper page
  63. Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC (2018) The serum exosome derived microRNA-135a, −193b, and −384 were potential Alzheimer’s disease biomarkers. Biomed Environ Sci 31(2):87–96
  64. Cosin-Tomas M, Antonell A, Llado A, Alcolea D, Fortea J, Ezquerra M et al (2017) Plasma miR-34a-5p and miR-545-3p as early biomarkers of Alzheimer’s disease: potential and limitations. Mol Neurobiol 54(7):5550–5562 · DOI
  65. Dangla-Valls A, Molinuevo JL, Altirriba J, Sanchez-Valle R, Alcolea D, Fortea J et al (2017) CSF microRNA profiling in Alzheimer’s disease: a screening and validation study. Mol Neurobiol 54(9):6647–6654 · DOI
  66. Guo R, Fan G, Zhang J, Wu C, Du Y, Ye H et al (2017) A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer’s disease. J Alzheimers Dis 60(4):1365–1377 · DOI
  67. Lusardi TA, Phillips JI, Wiedrick JT, Harrington CA, Lind B, Lapidus JA et al (2017) MicroRNAs in human cerebrospinal fluid as biomarkers for Alzheimer’s disease. J Alzheimers Dis 55(3):1223–1233 · DOI
  68. Nagaraj S, Laskowska-Kaszub K, Debski KJ, Wojsiat J, Dabrowski M, Gabryelewicz T et al (2017) Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects. Oncotarget. 8(10):16122–16143 · DOI
  69. Riancho J, Vazquez-Higuera JL, Pozueta A, Lage C, Kazimierczak M, Bravo M et al (2017) MicroRNA profile in patients with Alzheimer’s disease: analysis of miR-9-5p and miR-598 in raw and exosome enriched cerebrospinal fluid samples. J Alzheimers Dis 57(2):483–491 · DOI · Paper page
  70. Wu Y, Xu J, Cheng J, Jiao D, Zhou C, Dai Y et al (2017) Lower serum levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer’s disease. Tohoku J Exp Med 242(2):129–136 · DOI
  71. Jia LH, Liu YN (2016) Downregulated serum miR-223 servers as biomarker in Alzheimer’s disease. Cell Biochem Funct 34(4):233–237 · DOI · Paper page
  72. Keller A, Backes C, Haas J, Leidinger P, Maetzler W, Deuschle C et al (2016) Validating Alzheimer’s disease micro RNAs using next-generation sequencing. Alzheimers Dement 12(5):565–576 · DOI
  73. Muller M, Jakel L, Bruinsma IB, Claassen JA, Kuiperij HB, Verbeek MM (2016) MicroRNA-29a is a candidate biomarker for Alzheimer’s disease in cell-free cerebrospinal fluid. Mol Neurobiol 53(5):2894–2899 · DOI
  74. Ragusa M, Bosco P, Tamburello L, Barbagallo C, Condorelli AG, Tornitore M et al (2016) miRNAs plasma profiles in vascular dementia: biomolecular data and biomedical implications. Front Cell Neurosci 10:51 · DOI
  75. Ren RJ, Zhang YF, Dammer EB, Zhou Y, Wang LL, Liu XH et al (2016) Peripheral blood microRNA expression profiles in Alzheimer’s disease: screening, validation, association with clinical phenotype and implications for molecular mechanism. Mol Neurobiol 53(8):5772–5781 · DOI
  76. Xing H, Guo S, Zhang Y, Zheng Z, Wang H (2016) Upregulation of microRNA-206 enhances lipopolysaccharide-induced inflammation and release of amyloid-beta by targeting insulin-like growth factor 1 in microglia. Mol Med Rep 14(2):1357–1364 · DOI
  77. Yilmaz SG, Erdal ME, Ozge AA, Sungur MA (2016) Can peripheral microRNA expression data serve as epigenomic (upstream) biomarkers of Alzheimer’s disease? OMICS 20(8):456–461 · DOI
  78. Zhang Y, Liu C, Wang J, Li Q, Ping H, Gao S et al (2016) MiR-299-5p regulates apoptosis through autophagy in neurons and ameliorates cognitive capacity in APPswe/PS1dE9 mice. Sci Rep 6:24566 · DOI
  79. Zhang Y, Xing H, Guo S, Zheng Z, Wang H, Xu D (2016) MicroRNA-135b has a neuroprotective role via targeting of beta-site APP-cleaving enzyme 1. Exp Ther Med 12(2):809–814 · DOI
  80. Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A et al (2015) Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry 20(10):1188–1196 · DOI · Paper page
  81. Dong H, Li J, Huang L, Chen X, Li D, Wang T et al (2015) Serum microRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer’s disease. Dis Markers 2015:625659
  82. Guedes JR, Santana I, Cunha C, Duro D, Almeida MR, Cardoso AM et al (2015) MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer’s disease. Alzheimers Dement (Amst) 3:7–17 · DOI
  83. Gui Y, Liu H, Zhang L, Lv W, Hu X (2015) Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget. 6(35):37043–37053 · DOI · Paper page
  84. van Harten AC, Mulders J, Scheltens P, van der Flier WM, Oudejans CB (2015) Differential expression of microRNA in cerebrospinal fluid as a potential novel biomarker for Alzheimer’s disease. J Alzheimers Dis 47(1):243–252 · DOI · Paper page
  85. Wang T, Chen K, Li H, Dong S, Su N, Liu Y et al (2015) The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment. J Clin Psychiatry 76(2):135–141 · DOI
  86. Yang G, Song Y, Zhou X, Deng Y, Liu T, Weng G et al (2015) MicroRNA-29c targets beta-site amyloid precursor protein-cleaving enzyme 1 and has a neuroprotective role in vitro and in vivo. Mol Med Rep 12(2):3081–3088 · DOI
  87. Zhu Y, Li C, Sun A, Wang Y, Zhou S (2015) Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer’s disease. Exp Ther Med 9(3):1013–1017 · DOI
  88. Bhatnagar S, Chertkow H, Schipper HM, Yuan Z, Shetty V, Jenkins S et al (2014) Increased microRNA-34c abundance in Alzheimer’s disease circulating blood plasma. Front Mol Neurosci 7:2 · DOI
  89. Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T et al (2014) Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and Parkinson’s diseases correlate with disease status and features of pathology. PLoS One 9(5):e94839 · DOI · Paper page
  90. Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H, Miyazawa T (2014) MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J Alzheimers Dis 39(2):253–259 · DOI · Paper page
  91. geng Liu C, ling Wang J, Li L, xiang Xue L, qi Zhang Y, chang Wang P (2014) MicroRNA-135a and-200b, potential biomarkers for Alzheimer’s disease, regulate beta secretase and amyloid precursor protein. Brain Res 1583:55–64 · DOI
  92. Tan L, Yu JT, Liu QY, Tan MS, Zhang W, Hu N et al (2014) Circulating miR-125b as a biomarker of Alzheimer’s disease. J Neurol Sci 336(1–2):52–56 · DOI
  93. Tan L, Yu JT, Tan MS, Liu QY, Wang HF, Zhang W et al (2014) Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer’s disease. J Alzheimers Dis 40(4):1017–1027 · DOI
  94. Tiribuzi R, Crispoltoni L, Porcellati S, Lullo MD, Florenzano F, Pirro M et al (2014) miR128 up-regulation correlates with impaired amyloid beta(1-42) degradation in monocytes from patients with sporadic Alzheimer’s disease. Neurobiol Aging 35(2):345–356 · DOI · Paper page
  95. Bekris LM, Lutz F, Montine TJ, Yu CE, Tsuang D, Peskind ER et al (2013) MicroRNA in Alzheimer’s disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers. 18(5):455–466. https://doi.org/10.3109/1354750X.2013.814073 · DOI · Paper page
  96. Kumar P, Dezso Z, MacKenzie C, Oestreicher J, Agoulnik S, Byrne M et al (2013) Circulating miRNA biomarkers for Alzheimer’s disease. PLoS One 8(7):e69807 · DOI
  97. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K et al (2013) A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol 14(7):R78 · DOI
  98. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, Baumgart J et al (2012) An unconventional role for miRNA: let-7 activates toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 15(6):827–835 · DOI · Paper page
  99. Villa C, Fenoglio C, Riz MD, Clerici F, Marcone A, Benussi L et al (2011) Role of hnRNP-A1 and miR-590-3p in neuronal death: genetics and expression analysis in patients with Alzheimer disease and frontotemporal lobar degeneration. Rejuvenation Res 14(3):275–281 · DOI
  100. Schipper HM, Maes OC, Chertkow HM, Wang E (2007) MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Biol 1:263–274
  101. Sheinerman KS, Tsivinsky VG, Abdullah L, Crawford F, Umansky SR (2013) Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. Aging (Albany NY) 5(12):925–938. https://doi.org/10.18632/aging.100624 · DOI
  102. Swarbrick S, Wragg N, Ghosh S, Stolzing A (2019) Systematic review of miRNA as biomarkers in Alzheimer’s disease. Mol Neurobiol. https://doi.org/10.1007/s12035-019-1500-y · DOI
  103. Fransquet PD, Ryan J (2018) Micro RNA as a potential blood-based epigenetic biomarker for Alzheimer’s disease. Clin Biochem 58:5–14. https://doi.org/10.1016/j.clinbiochem.2018.05.020 · DOI
  104. Dickson JR, Kruse C, Montagna DR, Finsen B, Wolfe MS (2013) Alternative polyadenylation and miR-34 family members regulate tau expression. J Neurochem 127(6):739–749. https://doi.org/10.1111/jnc.12437 · DOI
  105. Pogue AI, Cui JG, Li YY, Zhao Y, Culicchia F, Lukiw WJ (2010) Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. Neurosci Lett 476(1):18–22. https://doi.org/10.1016/j.neulet.2010.03.054 · DOI
  106. Basavaraju M, de Lencastre A (2016) Alzheimer’s disease: presence and role of microRNAs. Biomol Concepts 7(4):241–252. https://doi.org/10.1515/bmc-2016-0014 · DOI
  107. Lukiw WJ, Andreeva TV, Grigorenko AP, Rogaev EI (2012) Studying micro RNA function and dysfunction in Alzheimer’s disease. Front Genet 3:327. https://doi.org/10.3389/fgene.2012.00327 · DOI
  108. Selkoe DJ (2008) Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer’s disease. Handb Clin Neurol 89:245–260. https://doi.org/10.1016/S0072-9752(07)01223-7 · DOI · Paper page
  109. Goedert M (2004) Tau protein and neurodegeneration. Semin Cell Dev Biol 15(1):45–49 · DOI · Paper page
  110. Slota JA, Booth SA (2019) MicroRNAs in neuroinflammation: implications in disease pathogenesis, biomarker discovery and therapeutic applications. Noncoding RNA 5:2. https://doi.org/10.3390/ncrna5020035 · DOI
  111. Gaudet AD, Fonken LK, Watkins LR, Nelson RJ, Popovich PG (2018) MicroRNAs: roles in regulating neuroinflammation. Neuroscientist. 24(3):221–245. https://doi.org/10.1177/1073858417721150 · DOI · Paper page
  112. Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K et al (2000) Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem 275(52):41340–41349. https://doi.org/10.1074/jbc.M006219200 · DOI
  113. Shal B, Ding W, Ali H, Kim YS, Khan S (2018) Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer’s disease. Front Pharmacol 9:548. https://doi.org/10.3389/fphar.2018.00548 · DOI · Paper page
  114. Piedrahita D, Hernández I, López-Tobón A, Fedorov D, Obara B, Manjunath BS et al (2010) Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer's mice. J Neurosci 30(42):13966–13976 · DOI
  115. Masliah E (1995) Mechanisms of synaptic dysfunction in Alzheimer’s disease. Histol Histopathol 10(2):509–519
  116. Masliah E, Mallory M, Hansen L, DeTeresa R, Terry RD (1993) Quantitative synaptic alterations in the human neocortex during normal aging. Neurology. 43(1):192–197 · DOI
  117. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65(7):631–641 · DOI · Paper page
  118. Stanley M, Macauley SL, Holtzman DM (2016) Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence? J Exp Med 213(8):1375–1385. https://doi.org/10.1084/jem.20160493 · DOI
  119. de la Monte SM, Tong M, Daiello LA, Ott BR (2019) Early-stage Alzheimer’s disease is associated with simultaneous systemic and central nervous system dysregulation of insulin-linked metabolic pathways. J Alzheimers Dis. https://doi.org/10.3233/JAD-180906 · DOI
  120. de la Monte SM (2012) Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease. Drugs. 72(1):49–66. https://doi.org/10.2165/11597760-000000000-00000 · DOI · Paper page
  121. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D et al (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101(9):3100–3105. https://doi.org/10.1073/pnas.0308724101 · DOI
  122. Craft S (2007) Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4(2):147–152 · DOI · Paper page
  123. de la Monte SM (2014) Type 3 diabetes is sporadic Alzheimer’s disease: mini-review. Eur Neuropsychopharmacol 24(12):1954–1960. https://doi.org/10.1016/j.euroneuro.2014.06.008 · DOI
  124. Newsholme P, Morgan D, Rebelato E, Oliveira-Emilio HC, Procopio J, Curi R et al (2009) Insights into the critical role of NADPH oxidase(s) in the normal and dysregulated pancreatic beta cell. Diabetologia. 52(12):2489–2498. https://doi.org/10.1007/s00125-009-1536-z · DOI
  125. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z et al (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J 18(7):902–904. https://doi.org/10.1096/fj.03-0978fje · DOI
  126. Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H et al (2016) Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 1:1
  127. Bassani TB, Vital MA, Rauh LK (2015) Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs. Arq Neuropsiquiatr 73(7):616–623. https://doi.org/10.1590/0004-282X20150057 · DOI · Paper page
  128. Longpré F, Garneau P, Christen Y, Ramassamy C (2006) Protection by EGb 761 against beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation. Free Radic Biol Med 41(12):1781–1794. https://doi.org/10.1016/j.freeradbiomed.2006.08.015 · DOI
  129. O’Neill LA, Kaltschmidt C (1997) NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 20(6):252–258 · DOI · Paper page
  130. Marchegiani F, Matacchione G, Ramini D, Marcheselli F, Recchioni R, Casoli T et al (2019) Diagnostic performance of new and classic CSF biomarkers in age-related dementias. Aging (Albany NY) 11(8):2420–2429. https://doi.org/10.18632/aging.101925 · DOI
  131. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198 · DOI · Paper page
  132. Nelson-Gray RO (1991) DSM-IV: empirical guidelines from psychometrics. J Abnorm Psychol 100(3):308–315 · DOI
  133. Kopkova A, Sana J, Fadrus P, Slaby O (2018) Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors. Clin Chem Lab Med 56(6):869–879. https://doi.org/10.1515/cclm-2017-0958 · DOI

Cited by

Sorted by citations

See all 81

Metadata

Authors
Herrera-Espejo, S., Santos-Zorrozua, B., Álvarez-González, P., Lopez-Lopez, E., & Garcia-Orad, Á.
ORCID
Lopez-Lopez, Elixabet
Venue
Molecular Neurobiology
Publisher
Springer Science and Business Media LLC
Published
2019-06-25
Volume
56
Issue
12
Pages
8376-8391
ISSN
  • 0893-7648
  • 1559-1182
DOI
10.1007/s12035-019-01676-9
Cited by
81
References
16
Language
en
Licence
Funders
Eusko Jaurlaritza (IT989-16)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review